The effects of the 5-hydroxytryptamine (5HT3) receptor antagonist ICS 205-930 in the carcinoid syndrome |
| |
| Authors: | M. O. COUPE J. V. ANDERSON J. A. MORRIS E. M. ALSTEAD S. R. BLOOM H. J. F. HODGSON |
| |
| Affiliation: | Department of Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, UK. |
| |
| Abstract: | Therapy for diarrhoea associated with the carcinoid syndrome is often unsatisfactory. In an open study ICS 205-930 (Sandoz Limited), a novel 5HT3-antagonist, controlled diarrhoea in five of six patients studied. This drug may be a useful advance in the symptomatic treatment of the carcinoid syndrome. |
| |
| Keywords: | |
|
|
